Fiscal Year 2027 U.S. Investment Case for the Global Fund


52 HIV, TB and malaria disease programs across 38 countries have transitioned from the Global Fund since 2002.

In the current financing cycle, we will see the largest transition from Global Fund support to date – 12 programs from eight countries.

At least 15% of grant funding is conditioned on meeting co-financing requirements.



Decades of progress on malaria is stalling and, in some countries, reversing sharply, following funding cuts in 2025. We expect dire figures on malaria cases and deaths for 2025. Unless we act with urgency now, 2026 will be even worse.

Drug resistance is spreading across Africa. Conflict, displacement and severe weather events are reshaping transmission patterns. Surveillance systems and bed net distribution campaigns have been disrupted. For example, major malaria resurgences are emerging across Nigeria and the Democratic Republic of the Congo.